Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
What Drives Dendritic Spine Loss? Study Taps Cdk5
3 December 2006. Neurons cannot afford to be spineless. Not only are those dendritic protrusions essential for transmitting incoming signals from other neurons, but their continual growth and retraction endows neural networks with the plasticity essential for learning and memory. In fact, reduction in dendritic spine density is one of the earliest pathological markers in mouse models of Alzheimer disease (see ARF related news story) and possibly in human disease, too, where learning and memory problems surface long before amyloid plaques and neurofibrillary tangles. So whatever factors drive loss of dendritic spines could be key pieces to the AD puzzle.

One of those factors is none other than the serine/threonine kinase Cdk5. In today’s Nature Neuroscience online, Nancy Ip and colleagues at the Hong Kong University of Science and Technology report that the kinase is crucial for dendritic spine retraction in hippocampal neurons. The finding places Cdk5, already linked to Aβ and tau pathology, at the scene of perhaps one of the earliest AD pathologies.

Ip and colleagues, including collaborators Michael Greenberg and coworkers at Children’s Hospital, Boston, discovered the spineless side to Cdk5 when studying the Eph family of receptor tyrosine kinases, which play key roles in synaptic remodeling. When activated by ephrins, EphBs help drive spine morphogenesis, while EphAs, in particular EphA4, drive spine retraction in hippocampal neurons (see Murai et al., 2003). Though what happens downstream of EphA4 activation has remained a bit of a mystery, the researchers wondered if Cdk5 might be involved, given that the serine/threonine kinase localizes to postsynaptic regions. To test this idea, joint first authors Wing-Yu Fu and Yu Chen added the Cdk5 inhibitor roscovitine to hippocampal slices, then challenged them with ephrin-A1. They found that roscovitine completely blocked spine retraction. They were also able to prevent spine loss in cultured hippocampal neurons by knocking down Cdk5 with RNAi.

The researchers went on to find that Cdk5 and its activator p35 interact with EphA4, and that activation of the latter by ephrin causes an increase in Cdk5 activity, most likely by phosphorylating the kinase at tyrosine 15—in cells expressing a Y15F Cdk5, mutant ephrin-A1 failed to have any effect on dendritic spine number. The researchers found that downstream of this interaction, Cdk5 was necessary for activation of the GTPase RhoA and for clustering of EphA4 on the cell membrane, an important step in recruitment and activation of other downstream signaling molecules including the guanidine exchange factor ephexin-1. In fact, Fu, Chen, and colleagues determined that Cdk5 phosphorylates ephexin-1, thereby inducing activation of RhoA, which is intimately involved in regulating cytoskeletal actin in dendritic spines—RhoA has also been implicated in ectodomain shedding and activation of γ-secretase (see ARF related news story). All told, the data point to Cdk5 as a major conduit for ephrin signals to the cytoskeleton.

Cdk5 is perhaps best known for regulating neurodevelopment, and its involvement in spine retraction would fit that role, especially as the authors found that ephrin-A1 causes spine loss in hippocampal neurons as early as postnatal day 7. The effects also seem physiologically significant because Ip and colleagues report that ephrin-driven spine retraction causes a decrease in synapses and a concomitant reduction in mini-excitatory postsynaptic currents (these are widely accepted as reflecting synapse number). In this respect, it is worth noting that p35-/- mice exhibit impaired long-term potentiation and long-term depression, which might be explained by poor spine regulation, though it might also be a direct result of neurodevelopmental problems.

Whether Cdk5-mediated spine loss has any pathological significance is not yet clear. But there has been much interest in the role of Cdk5 in neurodegenerative diseases of late, especially because of the potential involvement of the kinase in tau and Aβ pathology in AD. That dark side of Cdk5 has been linked to p25, the highly stable fragment of p35. Constitutive activation of Cdk5 by p25 can drive phosphorylation of tau (see ARF related news story) and production of intraneuronal Aβ (see Cruz et al., 2006 and ARF related news story). But interestingly, Ip and colleagues report that though Cdk5-p35 interacts with the EphA4 receptor, Cdk5-p25 does not, suggesting that spines may be spared in situations where p25 is upregulated, as in AD brain (see ARF related news story).—Tom Fagan.

Reference:
Fu W-Y, Chen Y, Sahin M, Zhao X-S, Shi L, Bikoff JB, Lai K-O, Yung W-H, Fu AKY, Greenberg ME, Ip NY. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. Nature Neurosci. Advanced online publication. December 3, 2006. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad